Drug Discovery World

APRIL 16, 2024

Recombinant adeno-associated viruses (rAAVs) are considered a promising delivery system for gene therapy medicines. This webinar will highlight how long-read nanopore sequencing as a comprehensive and sensitive QC method for rAAVs were evaluated — which is supporting internal research activities at AstraZeneca.

Packaging 52

Packaging Packaging Genome Genomics 52

Drug Discovery World

MAY 22, 2023

Ryan Leahy , a science communication expert in cell and gene therapy, at Phacilitate, says there is a lot to celebrate but also much to assess, question and challenge in this sector. The post No sign of stopping: The rise of cell and gene therapy appeared first on Drug Discovery World (DDW).

Gene Therapy 52

Gene Therapy Gene Drugs Contamination 52

Drug Discovery World

MAY 1, 2024

Recombinant adeno-associated viruses (rAAVs) are considered a promising delivery system for gene therapy medicines. The event will feature experts Daniel Jachimowicz, Senior Bioscience Scientist at AstraZeneca BioPharmaceuticals R&D, Sweden, and Bastian Schiffthaler, Senior Data Scientist at AstraZeneca BioPharmaceuticals R&D, Sweden.

Packaging 52

Packaging Packaging Genome Genomics 52

Drug Discovery World

APRIL 24, 2024

Recombinant adeno-associated viruses (rAAVs) are considered a promising delivery system for gene therapy medicines. The event will feature experts Daniel Jachimowicz, Senior Bioscience Scientist at AstraZeneca BioPharmaceuticals R&D, Sweden, and Bastian Schiffthaler, Senior Data Scientist at AstraZeneca BioPharmaceuticals R&D, Sweden.

Genome 52

Genome Genomics DNA Gene Therapy 52

Drug Discovery World

MAY 19, 2023

This paid-for advertorial by Astrea Bioseparations appeared in DDW Volume 24 – Issue 1, Winter 2022/2023 – Cell and Gene Therapy Guide. Therapeutic developers face significant challenges in purifying cell and gene therapy (CGT) modalities.

Contamination 52

Contamination Gene Therapy Gene Production 52

Advarra

JULY 28, 2022

This article explores how these tools work and why biosafety cabinets are preferred in research involving cell and gene therapies. Use of hazardous materials in a clean bench can increase the risk of occupational exposure and contamination of the room in which the work is being done. What is a Biosafety Cabinet?

Contamination 52

Contamination Biohazard Biohazard Production 52

Camargo

NOVEMBER 29, 2021

Gene and cellular therapies. They may contain proteins that control the action of other proteins and cellular processes, genes that control production of vital proteins, modified human hormones, or cells that produce substances that suppress or activate components of the immune system. Blood and blood components. Allergenics.

Development 180

Development Protein Production Hormones 180

Advarra

MARCH 31, 2023

The use of engineered genetic materials in clinical trials is rapidly expanding, with potential applications for genetic vaccines, gene-modified cellular therapies, and gene therapies. Gene Delivery Systems Genetic material, in the form of DNA or RNA, does not easily enter cells without the aid of a delivery system.

Engineer 52

Engineer Genetics Clinical Research Research 52

Drug Discovery World

MARCH 21, 2023

The team used two safeguard methods to prevent the bacteria and their modified genes from escaping into the wild. The work promises to reduce the threats of viral contamination when harnessing bacteria to produce medicines such as insulin as well as other useful substances, such as biofuels.

Engineer 52

Engineer Genetic Engineering Scientist Bacteria 52

Pharmaceutical Technology

APRIL 4, 2023

There are 13 sites in the region that offer API biologic services and 12 of these are based in Telangana, all offering protein and peptide manufacturing, and one – Loka Biosciences (Hyderabad, Telangana, India) – also offers gene therapy production. Source: GlobalData, Pharma Intelligence Center Drug Database (Accessed March 20, 2023).

Manufacturing 130

Manufacturing Generic Drugs Contract Manufacturing Production 130

Roots Analysis

APRIL 15, 2024

These complex entities, such as antibodies, antibody drug conjugates, cell therapies, gene therapies, and therapeutic proteins, are highly specific molecules that are designed to precisely target biomarkers associated with a particular disease pathway.

Manufacturing 40

Manufacturing Production Contract Manufacturing Contamination 40

XTalks

JULY 26, 2021

The authors concluded that the relatively high levels of the bacteria enterococci indicated that food safety was a concern for these products due to potential infections, antibiotic resistance and gene transfer associated with the bacteria E. The storage and handling of these products should mimic that of raw meats,” the authors wrote.

Protein 98

Protein Contamination Allergies Bacteria 98

The Pharma Data

JANUARY 10, 2021

Recent research has shown that virus contamination of environmental surfaces may lead to viral transfer and therefore an acceleration of outbreaks. The kit is highly specific for the two regions N1/N2 on the SARS-CoV-2 N-gene, ensuring reliable results with a two target approach.

RNA 52

RNA Reagent Contamination Gene 52

Roots Analysis

SEPTEMBER 20, 2023

It is important to highlight that cell and gene therapies have been used to treat an array of medical conditions for which no other treatments are available. Contamination is a key concern when it comes to manufacturing cell therapy products.

Manufacturing 40

Manufacturing Production Contamination Gene Therapy 40

Roots Analysis

OCTOBER 24, 2023

The limitations of stainless-steel bioreactors such as high risk of contamination, process related challenges and high operational cost have prompted innovators to develop more advanced single use bioreactor in order to meet the rising demand for safe and efficacious biotherapeutics.

Manufacturing 40

Manufacturing Contamination Marketing Production 40

pharmaphorum

MARCH 22, 2022

The challenges posed to manufacture these new therapies falls in line with the complexity of the therapies themselves, with a number of breakthroughs in the next generation of therapies being particularly challenging to produce at scale, such as cell and gene therapies. Taking manufacturing to the next level.

Manufacturing 136

Manufacturing Production Contamination Gene Therapy 136

Roots Analysis

AUGUST 30, 2023

Further, in the same year, nearly half of the biologic approvals were allotted to novel class of modalities, including antibody drug conjugates (ADCs), bispecific antibodies, cell therapies and gene therapies. Specifically, advancements in niche segments is expected to culminate in accelerated growth of the biologics market.

Manufacturing 40

Manufacturing Production Contamination Gene Therapy 40

FDA Law Blog

NOVEMBER 1, 2022

USP opened the workshop with a description of its organization, each of its applicable standards for advanced therapies, including its standards (general chapters) <1046> Cell and Tissue Based Products and <1047> Gene Therapy Products, and its microbial related chapters open for comment: <74> Solid Phase Cytometry-Based Rapid (..)

Manufacturing 59

Manufacturing Production Development Drugs 59

Drug Discovery World

MAY 11, 2023

Kerstin Pohl , Senior Global Marketing Manager, Gene Therapy & Nucleic Acid at SCIEX, looks at the application of liquid chromatography-mass spectrometry for analysing host cell proteins. Gene-based therapeutics and vaccines hold immense potential for more efficient and personalised treatment and prevention of complex diseases.

Production 52

Production Gene Protein Vaccination 52

Pharmaceutical Technology

FEBRUARY 3, 2023

With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more. So, we set out to solve some of the problems,” she explains.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Roots Analysis

OCTOBER 11, 2023

To balance these factors, we can expect to see an increased collaboration between manufacturers, suppliers, and regulatory agencies to ensure safe, and contamination-free bio innovations. The following figure presents some of the key market drivers and restraints in the agricultural biologicals domain.

Production 40

Production Bacteria Marketing Gene Editing 40

Drug Discovery World

JANUARY 19, 2023

This paid-for advertorial by Catalent appeared in DDW Volume 24 – Issue 1, Winter 2022/2023 One significant challenge in the manufacturing of cell and gene therapies is the production of high-quality plasmid DNA (pDNA). Figure 1: The integrated development pathway for cell and gene therapies. billion by 2030 (BioSpace, 11 August 2022).

DNA 52

DNA Manufacturing Gene Therapy Gene 52

Drug Discovery World

AUGUST 10, 2022

For example, one clinical trial examined the safety and efficacy of a CAR T cell that includes a suicide gene, which produces a toxic protein that causes the CAR T cells to die upon exposure to a drug 10. If the gene does not integrate into the genome, the cell will not become a CAR T cell. Detecting replication-competent viruses.

Manufacturing 98

Manufacturing Gene Genome Genomics 98

Drug Discovery World

FEBRUARY 8, 2023

Svea Cheeseman , Refeyn, explains why better efficiency is needed to advance the production of viral vectors for use in gene therapies. Adeno-associated viruses (AAVs) are a promising, widely used vector for delivering gene therapies. Data were provided by the Cell and Gene Therapy Catapult (London, UK).

Gene Therapy 52

Gene Therapy Gene Antibody Production 52

XTalks

NOVEMBER 7, 2022

Such information can reveal details about tumor staging, tumor progression, heterogeneity, gene mutations and clonal evolution. However, Dr. Bahassi reported that the selection of CTCs using this method is often not very efficient and the CTC population is usually highly contaminated with leukocytes.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Drug Discovery World

FEBRUARY 28, 2023

Now, given the extraordinary success of the Covid-19 vaccines, the mRNA platform may bring renewed hope as researchers explore its potential to advance medicines for rare diseases. Interestingly, at least 80% of all rare diseases originate from monogenic mutations, meaning that they arise from mutations in a single gene 4.

Genetics 52

Genetics Genetic Analysis Vaccination Vaccine 52

Drug Discovery World

NOVEMBER 1, 2023

Taking place on day two of BIA BioProcess UK, the Dragon’s Den special session is focused on next generation analytical technologies and will see six companies compete for an audience vote. Chairing the session will be Julie Kerby, Managing Director of Technology and Process Innovation, Cell and Gene Therapy Catapult.

Life Science 52

Life Science Contamination Gene Therapy Manufacturing 52

Roots Analysis

SEPTEMBER 18, 2023

Biologics: Gene therapy and cell therapy-based futuristic treatments fall under the category of advanced therapy medicinal products ( ATMPs ) and offer opportunities to individuals suffering from a variety of illnesses, including various types of cancers.

Engineer 52

Engineer Containment In-Vivo Production 52

Drug Discovery World

FEBRUARY 28, 2023

Purus is an automated microwell plate cleaning system that removes chemical and biological contaminants from multiple wells, resulting in plates that can be used for new applications. The company’s Purus product is designed to reduce waste and cut costs for labs around the world.

Gene Editing 52

Gene Editing Production Scientist Contamination 52

Roots Analysis

FEBRUARY 1, 2024

In the absence of suitable temperature controlled packaging solutions, the products packaged, such as vaccines, biologics, cell and gene therapies might get exposed to extreme ambient temperatures. Microbial contamination due to poorly maintained freezers and fridges.

Packaging 40

Packaging Packaging Containment Production 40

The Pharma Data

MAY 13, 2021

every day are contaminated with at LEAST ONE TOXIC ingredient. food is “A food in which the gene from one species has been forced into the DNA of another species and the process itself creates all sorts of unpredicted side effects.”. These ingredients can be harmful and even LIFE THREATENING. A better definition of a G.M.O.

Production 52

Production Containment Genetics Doctors 52

XTalks

SEPTEMBER 14, 2020

Results are available in about 15 minutes, so the test is much faster than currently available tests which detect viral genes. There is also a risk of the mask becoming contaminated from viral droplets while on the face and once contaminated, the virus may get into the eyes, nose or mouth when the mask is removed.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92

Pharmaceutical Technology

MAY 17, 2023

One big challenge is contamination. It can cost millions of dollars to remove contamination from a manufacturing process and this causes a consequent delay to the preparation of the drug. As with contamination, variation in outcomes and product quality are often a result of the raw materials used.

Insulin 130

Insulin Production Manufacturing Contamination 130

Pharmaceutical Technology

APRIL 27, 2023

GlobalData pharmaceutical analysts project that RNA-based gene therapies for oncology will grow from zero in 2022 to $4.6 Every stage of development should result in a reproducible, safe drug product with no cross contamination from one batch to another. billion by 2028.

Manufacturing 130

Manufacturing RNA Contamination Vaccination 130